Perspective Therapeutics Inc (CATX)
2.655
-0.06
(-2.03%)
USD |
NYAM |
Oct 09, 12:42
Perspective Therapeutics Gross Profit Margin (Quarterly) : -1.31K% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.31K% |
| March 31, 2026 | -1.38K% |
| December 31, 2025 | -2.25K% |
| September 30, 2025 | -270.8% |
| June 30, 2025 | -152.8% |
| March 31, 2025 | -114.0% |
| December 31, 2024 | -203.0% |
| September 30, 2024 | -81.30% |
| June 30, 2024 | -8.75% |
| March 31, 2024 | -9.54% |
| September 30, 2023 | 24.28% |
| June 30, 2023 | 55.27% |
| March 31, 2023 | 14.59% |
| June 30, 2022 | 36.97% |
| March 31, 2022 | 49.52% |
| December 31, 2021 | 43.32% |
| September 30, 2021 | 40.13% |
| June 30, 2021 | 49.67% |
| March 31, 2021 | 52.38% |
| December 31, 2020 | 49.47% |
| September 30, 2020 | 52.27% |
| June 30, 2020 | 46.99% |
| March 31, 2020 | 59.24% |
| December 31, 2019 | 50.36% |
| September 30, 2019 | 53.39% |
| Date | Value |
|---|---|
| June 30, 2019 | 45.69% |
| March 31, 2019 | 45.69% |
| December 31, 2018 | 40.18% |
| September 30, 2018 | 33.55% |
| June 30, 2018 | 27.26% |
| March 31, 2018 | 38.72% |
| December 31, 2017 | 34.57% |
| September 30, 2017 | 21.88% |
| June 30, 2017 | 36.35% |
| March 31, 2017 | 22.85% |
| December 31, 2016 | -0.10% |
| September 30, 2016 | 4.44% |
| June 30, 2016 | -4.24% |
| March 31, 2016 | 5.53% |
| December 31, 2015 | 2.26% |
| September 30, 2015 | 6.62% |
| June 30, 2015 | 15.29% |
| March 31, 2015 | 4.51% |
| December 31, 2014 | -3.57% |
| September 30, 2014 | -5.26% |
| June 30, 2014 | -14.34% |
| March 31, 2014 | 4.49% |
| December 31, 2013 | -3.12% |
| September 30, 2013 | -7.36% |
| June 30, 2013 | 11.54% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Biogen, Inc. | 61.37% |
| Rigel Pharmaceuticals, Inc. | 89.17% |
| Enanta Pharmaceuticals, Inc. | 91.75% |
| Insight Molecular Diagnostics, Inc. | -202.5% |
| BridgeBio Pharma, Inc. | 93.68% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -42.07% |
| Return on Assets | -34.66% |
| Return on Invested Capital | -41.52% |
| Profit Margin (Quarterly) | -33.31K% |
| Operating Margin (Quarterly) | -36.12K% |
| Return on Net Operating Assets | -91.31% |